How has Xenon Pharmaceuticals's operating lease liabilities changed year-over-year?

Xenon Pharmaceuticals's operating lease liabilities decreased by 13.7% year-over-year, from -$307K to -$349K.

What is the long-term trend for Xenon Pharmaceuticals's operating lease liabilities?

Over 3 years (2022 to 2025), Xenon Pharmaceuticals's operating lease liabilities has grown at a 29.3% compound annual growth rate (CAGR), from -$600K to -$1.3M.

Xenon Pharmaceuticals XENE Operating lease liabilities

Operating lease liabilities at other companies

Axsome TherapeuticsAXSM

——

Praxis Precision Medicines, Inc.PRAX

——

BridgeBio PharmaBBIO

——

Roivant SciencesROIV

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$112.3M-54.4%

Net income-$102.3M-57.3%

EPS (diluted)-$1.17-41.0%

Balance sheet

See full

Cash & equivalents$545.9M+368%

Total debt$7.5M-13.6%

Total equity$1.3B+90.0%

Total assets$1.4B+86.6%

Cash flow

See full

Operating cash flow-$88.9M-44.2%

CapEx$133.0K+209%

Free cash flow-$89.0M-44.3%

Valuation

See full

Market cap$5.11B+116%

Profitability

See full

Operating margin-4,974.3%—

Net margin-4,612.1%—

FCF margin-3,732.2%—

Returns & leverage

See full

Return on equity-37.5%+8.7pp

Debt / equity0×0.0×

Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xenon Pharmaceuticals's operating lease liabilities?: Xenon Pharmaceuticals (XENE) reported operating lease liabilities of -$349K in Q1 2026.
How has Xenon Pharmaceuticals's operating lease liabilities changed year-over-year?: Xenon Pharmaceuticals's operating lease liabilities decreased by 13.7% year-over-year, from -$307K to -$349K.
What is the long-term trend for Xenon Pharmaceuticals's operating lease liabilities?: Over 3 years (2022 to 2025), Xenon Pharmaceuticals's operating lease liabilities has grown at a 29.3% compound annual growth rate (CAGR), from -$600K to -$1.3M.